Despite significant fundraising results to date, Lyell Immunopharma has been stuck in neutral with its own cancer cell therapy efforts, and the firm revealed on 24 October that it is merging with privately held ImmPACT Bio, bringing that company’s Phase I chimeric antigen receptor T-cell (CAR-T) therapy candidate into its pipeline and shuttering some of its own existing R&D candidates. Among other changes, Lyell is ceasing its efforts in tumor-infiltrating lymphocyte (TIL) therapies.
Key Takeaways
- Lyell will pay $30m up front plus a sizeable equity stake to acquire ImmPACT Bio and its Phase I dual anti-CD19/20 CAR-T therapy for B-cell non-Hodgkin lymphoma.
On a same-day investor call, Lyell CEO Lynn Sealy said ImmPACT’s lead candidate, the dual-targeting CD19/20-directed CAR-T candidate IMPT-314, may...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?